Clinical stage biotechnology company Adicet Bio Inc (Nasdaq: ACET) announced on Wednesday that it has received FDA approval to amend its Investigational New Drug (IND) application to include idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) in its ongoing Phase 1 trial for ADI-001.
Patient enrollment for these cohorts is set to begin in the first quarter of 2025. ADI-001's clinical development now targets six autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).
Adicet plans to report initial data from its Phase 1 trial in the first half of 2025.
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
UCB and Biogen report positive Phase 3 results for dapirolizumab pegol in SLE
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Sareum Holdings secures patent allowance for SDC-1801 in China
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Carisma and Moderna expand collaboration
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Merck KGaA initiates Phase III trial for oral cladribine in gMG